Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta

Anna Paola Batocchi, Mario Rotondi, Marcella Caggiula, Giovanni Frisullo, Francesca Odoardi, Viviana Nociti, Carlo Carella, Pietro Attilio Tonali, Massimiliano Mirabella

Research output: Contribution to journalArticlepeer-review


The role of leptin was investigated in relapsing-remitting multiple sclerosis (MS). Control and MS patients showed comparable baseline serum leptin levels. During the first year of IFNbeta-1a treatment, leptin significantly decreased since 2 months after starting therapy in 11 patients who had no relapses. A significant decrease in IL12/IL10 ratio was observed in this group of patients only after 1 year of treatment. An increase of leptin was observed before the first clinical exacerbation in 13 relapsing patients. Leptin may play a pathogenic role in MS and can be a useful marker of disease activity and response to therapy.

Original languageEnglish
Pages (from-to)150-154
Number of pages5
JournalJournal of Neuroimmunology
Issue number1-2
Publication statusPublished - Jun 2003


  • Cytokines
  • Interferon beta
  • Leptin
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology


Dive into the research topics of 'Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta'. Together they form a unique fingerprint.

Cite this